ImmunityBio (IBRX) is higher as the market re-prices balance-sheet risk following disclosure of fresh non-dilutive capital and a founder-affiliated debt reduction. In its March 31, 2026 release tied to a March 30, 2026 Form 8-K, the company said it secured $75 million in additional funding under an amended revenue-interest agreement, and separately converted $25 million of a promissory note into equity (4.6 million shares), reducing outstanding debt. (sec.gov)

The 8-K describes a second amendment to the revenue interest purchase agreement, with purchasers paying $75 million and receiving a tiered percentage of net sales in the covered territory (with specified exclusions) until a capped multiple is reached. Management positioned the proceeds as funding for general corporate purposes and for scaling commercialization and global expansion. (sec.gov)

After a sharp drawdown tied to FDA-related promotional concerns and ensuing shareholder litigation headlines earlier in April, traders are rotating back to near-term fundamentals: liquidity, financing overhang, and whether commercialization can outpace obligations embedded in revenue-interest structures. The FDA warning letter episode drove a steep selloff in late March, keeping sentiment highly sensitive to any balance-sheet or execution update. (apnews.com)

Near-term focus remains on (1) follow-through in ANKTIVA sales trends and reimbursement traction, (2) any additional regulatory updates for label expansion efforts, and (3) headline risk from FDA promotional enforcement and class-action activity. Investors will also watch whether the added capital reduces the need for dilutive financing while the company pursues broader commercialization and pipeline development. (sec.gov)